Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Research

• Publication date

  2018-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-17-3034PMID 29610116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neuroblastoma

  2018cited by this paper
• The whole-genome landscape of medulloblastoma subtypes

  2017cited by this paper
• The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

  2016cited by this paper
• Glutathione biosynthesis is upregulated at the initiation of MYCN‐driven neuroblastoma tumorigenesis

  2016cited by this paper
• Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data

  2016cited by this paper
• The dual regulatory role of miR-204 in cancer

  2016cited by this paper
• Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma

  2015cited by this paper
• A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells

  2015cited by this paper
• WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

  2015cited by this paper
• miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth

  2015cited by this paper
• MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.

  2015cited by this paper
• A biochemical approach to identify direct microRNA targets.

  2015cited by this paper
• limma powers differential expression analyses for RNA-sequencing and microarray studies

  2015cited by this paper
• CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

  2014cited by this paper
• MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1

  2014cited by this paper
• miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A

  2014cited by this paper
• MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation

  2014cited by this paper
• Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.

  2014cited by this paper
• The prenatal origins of cancer

  2014cited by this paper
• EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.

  2014cited by this paper
• Drugging MYCN through an allosteric transition in Aurora kinase A.

  2014cited by this paper
• Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase

  2014cited by this paper
• Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma

  2013cited by this paper
• Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation

  2013cited by this paper
• Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

  2013cited by this paper
• The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease

  2013cited by this paper
• Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.

  2013cited by this paper
• Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.

  2013cited by this paper
• Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma

  2013cited by this paper
• Modulation of Neuroblastoma Disease Pathogenesis By An Extensive Network of Epigenetically Regulated MicroRNAs

  2012cited by this paper
• MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  2012cited by this paper
• miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer

  2012cited by this paper
• MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome

  2012cited by this paper
• LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression

  2012cited by this paper
• Non-coding RNAs in human disease

  2011cited by this paper
• Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

  2011cited by this paper
• A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.

  2011cited by this paper
• Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets.

  2011cited by this paper
• Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.

  2011cited by this paper
• miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples

  2011cited by this paper
• Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

  2010cited by this paper
• miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma

  2010cited by this paper
• p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC

  2010cited by this paper
• The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma.

  2010cited by this paper
• A novel and universal method for microRNA RT-qPCR data normalization

  2009cited by this paper
• Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

  2009cited by this paper
• MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.

  2009cited by this paper
• Exploring complex miRNA-mRNA interactions with Bayesian networks by splitting-averaging strategy

  2009cited by this paper
• ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

  2008cited by this paper
• Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis

  2007cited by this paper
• Oncomirs — microRNAs with a role in cancer

  2006cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Imperfect protection: NEPA at 35 years.

  2004cited by this paper
• Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

  2004cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• Molecular and Cellular Pathobiology Microrna Signature and Expression of Dicer and Drosha Can Predict Prognosis and Delineate Risk Groups in Neuroblastoma

  year unknowncited by this paper

• A Comprehensive Guide on Epigenetics' Precision Role in Uncommon "Rare" Cancers' Biology and Treatment Frontiers.

  2026cites this paper
• Molecular regulation and therapeutic targeting of MYCN in neuroblastoma: a comprehensive review

  2025cites this paper
• Trajectory analysis reveals an uncommitted neuroblastic state in MYCN-driven neuroblastoma development

  2025cites this paper
• Global burden, trends, and projections to 2050 of neuroblastoma and other peripheral nervous cell tumors: a systematic analysis of the global burden of disease study from 1990 to 2021

  2025cites this paper
• Emerging roles of pseudogene-derived lncRNAs in cancer stem cells: Non-coding clues and therapeutic targets in cancer medicine

  2025cites this paper
• Regulation and dysregulation of microRNA - transcription factor axes in differentiation and neuroblastoma

  2025influential citation
• Integrated genomics reveals cellular senescence‐driven molecular networks and immune crosstalk in myopia pathogenesis

  2025cites this paper
• Revisiting Neuroblastoma: Nrf2, NF-κB and Phox2B as a Promising Network in Neuroblastoma

  2024cites this paper
• Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics

  2024cites this paper
• Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

  2024cites this paper
• The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma

  2024cites this paper
• Development of red blood cell-derived extracellular particles as a biocompatible nanocarrier of microRNA-204 (REP-204) to harness anti-neuroblastoma effect.

  2024cites this paper
• Targeting Pediatric Solid Tumors in the New Era of RNA Therapeutics.

  2024cites this paper
• RNase H-dependent DNA thresholder modulated by cancer marker concentration.

  2024cites this paper
• The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics

  2023cites this paper
• Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma

  2023cites this paper
• MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression

  2023cites this paper
• Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275/AXIN2 in natural killer cells

  2023cites this paper
• Prognostic value of CASC15 and LINC01600 as competitive endogenous RNAs in lung adenocarcinoma: An observational study

  2023cites this paper
• Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma

  2023influential citation
• Red blood cell-derived extracellular vesicles with miR-204 mimic loading for pediatric neuroblastoma treatment

  2023cites this paper
• MicroRNAs as prospective biomarkers, therapeutic targets and pharmaceuticals in neuroblastoma

  2022cites this paper
• miR-99b-5p, miR-380-3p and miR-485-3p are novel chemosensitising miRNAs in high-risk neuroblastoma.

  2022cites this paper
• Clinical implications of noncoding RNAs in neuroblastoma patients

  2022cites this paper
• miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma

  2022cites this paper
• MicroRNAs in neural crest development and neurocristopathies

  2022cites this paper
• The role of ncRNAs in neuroblastoma: mechanisms, biomarkers and therapeutic targets

  2022cites this paper
• miR-204-5p in vivo inhibition cause diminished CD45RO cells rate in lungs of melanoma B16-bearing mice

  2022cites this paper
• TTF1 suppresses neuroblastoma growth and induces neuroblastoma differentiation by targeting TrkA and the miR-204/TrkB axis

  2022influential citation
• A 16-miRNA Prognostic Model to Predict Overall Survival in Neuroblastoma

  2022cites this paper
• MicroRNA‐204‐5p: A pivotal tumor suppressor

  2022cites this paper
• The clinical utility of dysregulated microRNA expression in paediatric solid tumours.

  2022cites this paper
• Overexpression of lncRNA TUG1 enhances the efficacy of DC-CIK immunotherapy in neuroblastoma in vitro and in vivo

  2022cites this paper
• The Contribution of Autophagy and LncRNAs to MYC-Driven Gene Regulatory Networks in Cancers

  2021influential citation
• Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-Myc-Amplified Form IMR5

  2021cites this paper
• MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation

  2021cites this paper
• A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma

  2021influential citation
• Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer

  2021cites this paper
• An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

  2021cites this paper
• A Common 3′UTR Variant of the PHOX2B Gene Is Associated With Infant Life-Threatening and Sudden Death Events in the Italian Population

  2021cites this paper
• Non-Coding RNAs Participate in the Pathogenesis of Neuroblastoma

  2021cites this paper
• Molecular Mechanisms of MYCN Dysregulation in Cancers

  2021cites this paper
• RNA‐Cleaving DNA Thresholder Controlled by Concentrations of miRNA Cancer Marker

  2021cites this paper
• TimiRGeN: R/Bioconductor package for time series microRNA–mRNA integration and analysis

  2021cites this paper
• An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

  2021cites this paper
• The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression

  2020cites this paper
• CUL4B contributes to cancer stemness by repressing tumor suppressor miR34a in colorectal cancer

  2020cites this paper
• Comprehensive Characterization of Circular RNAs in Neuroblastoma Cell Lines

  2020cites this paper
• miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.

  2020cites this paper
• MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma

  2020cites this paper
• Astragalus polysaccharide attenuates metabolic memory-triggered ER stress and apoptosis via regulation of miR-204/SIRT1 axis in retinal pigment epithelial cells

  2020cites this paper
• Crosstalk between oncogenic MYC and noncoding RNAs in cancer.

  2020cites this paper
• miR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma

  2019cites this paper
• MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution

  2019cites this paper
• Causative and common PHOX2B variants define a broad phenotypic spectrum

  2019cites this paper
• miR‑21 inhibitor facilitates the anticancer activity of doxorubicin loaded nanometer in melanoma.

  2019cites this paper
• miR-20a regulates sensitivity of colorectal cancer cells to NK cells by targeting MICA

  2019cites this paper
• Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells

  2019cites this paper
• MicroRNA‐493‐5p‐mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion

  2019cites this paper
• MicroRNA dysregulation interplay with childhood abdominal tumors

  2019cites this paper
• Constitutive Developmental Modeling of Genomic Integrity and Epigenetic Interactivity in Neuroblastoma

  2018cites this paper
• Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers collateral sensitivity to ALK inhibitors in high-risk neuroblastoma

  year unknowncites this paper